Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine

Autores
Mignaqui, Ana Clara; Ferella, Alejandra; Cass, Brian; Mukankurayija, Larissa; L’Abbé, Denis; Bisson, Louis; Sánchez, Cintia; Scian, Romina; Cardillo, Sabrina Beatriz; Durocher, Yves; Wigdorovitz, Andres
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Inactivated Foot-and-Mouth Disease (FMD) vaccine has proven to be effective in the control of the disease. However, its production has some disadvantages, including the costly biosafety facilities required for the production of huge amounts of growing live virus, the need of an exhaustive purification process to eliminate non-structural proteins of the virus in the final formulations in order to differentiate infected from vaccinated animals and variable local regulatory restrictions to produce and commercialize the vaccine. Thus, a novel vaccine against FMD that overcome these restrictions is desirable. Although many developments have been made in this regard, most of them failed in terms of efficacy or when considering their transferability to the industry. We have previously reported the use of transient gene expression in mammalian cells to produce FMD virus-like particles (VLPs) as a novel vaccine for FMD and demonstrated the immunogenicity of the recombinant structures in animal models. Here, we report the optimization of the production system by assaying different DNA:polyethylenimine concentrations, cell densities, and direct and indirect protocols of transfection. Also, we evaluated the reproducibility and scalability of the technology to produce high yields of recombinant VLPs in a cost-effective and scalable system compatible with industrial tech-transfer of an effective and safe vaccine.
Estación Experimental Agropecuaria Bariloche
Fil: Mignaqui, Ana Clara. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; Argentina
Fil: Ferella, Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Cass, Brian. Human Health Therapeutics Research Center, National Research Council Canada; Canadá
Fil Mukankurayija, Larissa. Human Health Therapeutics Research Center, National Research Council Canada; Canadá
Fil: L’Abbé, Denis. Human Health Therapeutics Research Center, National Research Council Canada; Canadá
Fil: Bisson, Louis. Human Health Therapeutics Research Center, National Research Council Canada; Canada
Fil: Sánchez, Cintia. Biogénesis-Bagó; Argentina
Fil: Scian, Romina. Biogénesis-Bagó; Argentina
Fil: Cardillo, Sabrina Beatriz. Biogénesis-Bagó; Argentina
Fil: Durocher, Yves. Human Health Therapeutics Research Center, National Research Council Canada; Canadá
Fil: Wigdorovitz, Andres. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fuente
Frontiers in Veterinary Science 7 : art. 601 (2020)
Materia
Vacuna Inactivada
Fiebre Aftosa
Enfermedades de los Animales
Inactivated Vaccines
Foot and Mouth Disease
Animal Diseases
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/8502
Acceder
id INTADig_2b39e189a53c8248948e019dee9a081a
oai_identifier_str oai:localhost:20.500.12123/8502
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation VaccineMignaqui, Ana ClaraFerella, AlejandraCass, BrianMukankurayija, LarissaL’Abbé, DenisBisson, LouisSánchez, CintiaScian, RominaCardillo, Sabrina BeatrizDurocher, YvesWigdorovitz, AndresVacuna InactivadaFiebre AftosaEnfermedades de los AnimalesInactivated VaccinesFoot and Mouth DiseaseAnimal DiseasesInactivated Foot-and-Mouth Disease (FMD) vaccine has proven to be effective in the control of the disease. However, its production has some disadvantages, including the costly biosafety facilities required for the production of huge amounts of growing live virus, the need of an exhaustive purification process to eliminate non-structural proteins of the virus in the final formulations in order to differentiate infected from vaccinated animals and variable local regulatory restrictions to produce and commercialize the vaccine. Thus, a novel vaccine against FMD that overcome these restrictions is desirable. Although many developments have been made in this regard, most of them failed in terms of efficacy or when considering their transferability to the industry. We have previously reported the use of transient gene expression in mammalian cells to produce FMD virus-like particles (VLPs) as a novel vaccine for FMD and demonstrated the immunogenicity of the recombinant structures in animal models. Here, we report the optimization of the production system by assaying different DNA:polyethylenimine concentrations, cell densities, and direct and indirect protocols of transfection. Also, we evaluated the reproducibility and scalability of the technology to produce high yields of recombinant VLPs in a cost-effective and scalable system compatible with industrial tech-transfer of an effective and safe vaccine.Estación Experimental Agropecuaria BarilocheFil: Mignaqui, Ana Clara. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; ArgentinaFil: Ferella, Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Cass, Brian. Human Health Therapeutics Research Center, National Research Council Canada; CanadáFil Mukankurayija, Larissa. Human Health Therapeutics Research Center, National Research Council Canada; CanadáFil: L’Abbé, Denis. Human Health Therapeutics Research Center, National Research Council Canada; CanadáFil: Bisson, Louis. Human Health Therapeutics Research Center, National Research Council Canada; CanadaFil: Sánchez, Cintia. Biogénesis-Bagó; ArgentinaFil: Scian, Romina. Biogénesis-Bagó; ArgentinaFil: Cardillo, Sabrina Beatriz. Biogénesis-Bagó; ArgentinaFil: Durocher, Yves. Human Health Therapeutics Research Center, National Research Council Canada; CanadáFil: Wigdorovitz, Andres. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFrontiers Media S.A.2020-12-28T16:45:30Z2020-12-28T16:45:30Z2020-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/8502https://www.frontiersin.org/articles/10.3389/fvets.2020.00601/full2297-1769https://doi.org/10.3389/fvets.2020.00601Frontiers in Veterinary Science 7 : art. 601 (2020)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-09-29T13:45:06Zoai:localhost:20.500.12123/8502instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-29 13:45:06.811INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
title Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
spellingShingle Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
Mignaqui, Ana Clara
Vacuna Inactivada
Fiebre Aftosa
Enfermedades de los Animales
Inactivated Vaccines
Foot and Mouth Disease
Animal Diseases
title_short Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
title_full Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
title_fullStr Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
title_full_unstemmed Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
title_sort Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
dc.creator.none.fl_str_mv Mignaqui, Ana Clara
Ferella, Alejandra
Cass, Brian
Mukankurayija, Larissa
L’Abbé, Denis
Bisson, Louis
Sánchez, Cintia
Scian, Romina
Cardillo, Sabrina Beatriz
Durocher, Yves
Wigdorovitz, Andres
author Mignaqui, Ana Clara
author_facet Mignaqui, Ana Clara
Ferella, Alejandra
Cass, Brian
Mukankurayija, Larissa
L’Abbé, Denis
Bisson, Louis
Sánchez, Cintia
Scian, Romina
Cardillo, Sabrina Beatriz
Durocher, Yves
Wigdorovitz, Andres
author_role author
author2 Ferella, Alejandra
Cass, Brian
Mukankurayija, Larissa
L’Abbé, Denis
Bisson, Louis
Sánchez, Cintia
Scian, Romina
Cardillo, Sabrina Beatriz
Durocher, Yves
Wigdorovitz, Andres
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Vacuna Inactivada
Fiebre Aftosa
Enfermedades de los Animales
Inactivated Vaccines
Foot and Mouth Disease
Animal Diseases
topic Vacuna Inactivada
Fiebre Aftosa
Enfermedades de los Animales
Inactivated Vaccines
Foot and Mouth Disease
Animal Diseases
dc.description.none.fl_txt_mv Inactivated Foot-and-Mouth Disease (FMD) vaccine has proven to be effective in the control of the disease. However, its production has some disadvantages, including the costly biosafety facilities required for the production of huge amounts of growing live virus, the need of an exhaustive purification process to eliminate non-structural proteins of the virus in the final formulations in order to differentiate infected from vaccinated animals and variable local regulatory restrictions to produce and commercialize the vaccine. Thus, a novel vaccine against FMD that overcome these restrictions is desirable. Although many developments have been made in this regard, most of them failed in terms of efficacy or when considering their transferability to the industry. We have previously reported the use of transient gene expression in mammalian cells to produce FMD virus-like particles (VLPs) as a novel vaccine for FMD and demonstrated the immunogenicity of the recombinant structures in animal models. Here, we report the optimization of the production system by assaying different DNA:polyethylenimine concentrations, cell densities, and direct and indirect protocols of transfection. Also, we evaluated the reproducibility and scalability of the technology to produce high yields of recombinant VLPs in a cost-effective and scalable system compatible with industrial tech-transfer of an effective and safe vaccine.
Estación Experimental Agropecuaria Bariloche
Fil: Mignaqui, Ana Clara. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; Argentina
Fil: Ferella, Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Cass, Brian. Human Health Therapeutics Research Center, National Research Council Canada; Canadá
Fil Mukankurayija, Larissa. Human Health Therapeutics Research Center, National Research Council Canada; Canadá
Fil: L’Abbé, Denis. Human Health Therapeutics Research Center, National Research Council Canada; Canadá
Fil: Bisson, Louis. Human Health Therapeutics Research Center, National Research Council Canada; Canada
Fil: Sánchez, Cintia. Biogénesis-Bagó; Argentina
Fil: Scian, Romina. Biogénesis-Bagó; Argentina
Fil: Cardillo, Sabrina Beatriz. Biogénesis-Bagó; Argentina
Fil: Durocher, Yves. Human Health Therapeutics Research Center, National Research Council Canada; Canadá
Fil: Wigdorovitz, Andres. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
description Inactivated Foot-and-Mouth Disease (FMD) vaccine has proven to be effective in the control of the disease. However, its production has some disadvantages, including the costly biosafety facilities required for the production of huge amounts of growing live virus, the need of an exhaustive purification process to eliminate non-structural proteins of the virus in the final formulations in order to differentiate infected from vaccinated animals and variable local regulatory restrictions to produce and commercialize the vaccine. Thus, a novel vaccine against FMD that overcome these restrictions is desirable. Although many developments have been made in this regard, most of them failed in terms of efficacy or when considering their transferability to the industry. We have previously reported the use of transient gene expression in mammalian cells to produce FMD virus-like particles (VLPs) as a novel vaccine for FMD and demonstrated the immunogenicity of the recombinant structures in animal models. Here, we report the optimization of the production system by assaying different DNA:polyethylenimine concentrations, cell densities, and direct and indirect protocols of transfection. Also, we evaluated the reproducibility and scalability of the technology to produce high yields of recombinant VLPs in a cost-effective and scalable system compatible with industrial tech-transfer of an effective and safe vaccine.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-28T16:45:30Z
2020-12-28T16:45:30Z
2020-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/8502
https://www.frontiersin.org/articles/10.3389/fvets.2020.00601/full
2297-1769
https://doi.org/10.3389/fvets.2020.00601
url http://hdl.handle.net/20.500.12123/8502
https://www.frontiersin.org/articles/10.3389/fvets.2020.00601/full
https://doi.org/10.3389/fvets.2020.00601
identifier_str_mv 2297-1769
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers Media S.A.
publisher.none.fl_str_mv Frontiers Media S.A.
dc.source.none.fl_str_mv Frontiers in Veterinary Science 7 : art. 601 (2020)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1844619149900251136
score 12.559606

Publicaciones similares